gsk takeover bid - $1.00?, page-3

Bridgette
Dont want to be a killjoy,but I disagree with you.

The fact is that Relenza has never been a commercial success.
EVERY year many millions of people throughout the world get flu.
Tens of thousands die from it.
Despite this, the public have not taken to Relenza.

( This is the reason for my tongue in cheek posts recently about dosing birds with it...It needs a new market ! )

The main reason in my opinion that it hasn't taken on is because it is too complicated to use.
The inhaler device is an design & mechanical masterpiece.
But therein lies the problem.
One almost needs an engineering degree to figure it out.
The last thing a person who has flu & feels lousy & is not thinking too clearly needs, is to be confronted with this puzzle.

Much easier to take a tablet or capsule, which is why Tamiflu is more popular.

As far as R & D goes, Bioita would be an absolute minnow compared to the R & D conducted by GSK.
I would imagine they would prefer NOT to do R & D anyway if they could commercially exploit other peoples.

Bendigo